You searched for: consider (Grekiska - Engelska)

points to consider on missing data
points to consider on missing data

points to consider on the evaluation of
points to consider on the evaluation of diagnostic agents released for consultation november 2000

points to consider on xenogeneic cell therapy
concept paper on the development of a points to consider on xenogeneic cell therapy adopted november 2000

points to consider on adjustment for baseline covariates
points to consider on adjustment for baseline covariates

points to consider on the evaluation of diagnostic agents
points to consider on the evaluation of diagnostic agents

points to consider on multiplicity issues in clinical trials
points to consider on multiplicity issues in clinical trials

points to consider on xenogeneic cell therapy for medicinal products
points to consider on xenogeneic cell therapy for medicinal products

points to consider on the assessment of anti- hiv medicinal products
points to consider on the assessment of anti-hiv medicinal products

for example, consider two clocks at both mouths both showing the date as 2000.
for example, consider two clocks at both mouths both showing the date as 2000.

points to consider document on the need for reproduction studies in the development of insulin analogues
points to consider document on the need for reproduction studies in the development of insulin analogues

investigation of medicinal products in the treatment of diabetes mellitus points to consider on clinical investigation
concept paper on the development of a cpmp note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus adopted july 2000

and pharmacodynamics in the development of anti- bacterial medicinal products points to consider on switching between
points to consider on pharmaco-kinetics and pharmacodynamics in the development of anti-bacterial medicinal products adopted july 2000

points to consider on application with 1) meta - analyses and 2) one pivotal study
points to consider on application with 1) meta-analyses and 2) one pivotal study

concept paper on the development of a cpmp points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population.
concept paper on the development of a cpmp points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population

concept paper on the development of a cpmp points to consider document on the evaluation of new anti- fungal agents for invasive fungal infections
concept paper on the development of a cpmp points to consider document on the evaluation of new anti-fungal agents for invasive fungal infections

investigation of medicinal products in the treatment of asthma concept paper on the development of a cpmp points to consider on biostatistical/ methodological issues arising
concept paper on the development of a cpmp note for guidance on the clinical investigation of medicinal products in the treatment of asthma adopted february 2000

adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
adjustment for multiplicity and related topics points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:

2000 αν υονέ ιεκορπ εκηθόδκΕ points to consider on validity and ονε ίεκιτνα ιεσέλετοπα emea/ cpmp/ ewp/ 2330/ 99
emea/ cpmp/ ewp/2330/99

need for post- marketing data contribution to cpmp points to consider document on xenogeneic cell therapy proposals for revision to standard operating procedure on urgent safety restrictions for medicinal products authorised through the mutual recognition procedure
need for post-marketing data contribution to cpmp points to consider document on xenogeneic cell therapy proposals for revision to standard operating procedure on urgent safety restrictions for medicinal products authorised through the mutual recognition procedure

Τίτλος εγγράφου note for guidance on the use of bovine serum in the manufacture of human biological medicinal products points to consider on quality aspects of medicinal products containing active substances produced by stable transgene expression in higher plants revision of note for guidance on minimising the risks of tse transmission via medicinal products points to consider on the development of live attenuated influenza vaccines
containing active substances produced by stable transgene expression in higher plants